Global Antibody Partnering Deals Collection 2014-2020 - Access to 1,300+ Online Deal Records; Headline, Upfront, Milestone and Royalty Data

News provided by

Jul 10, 2020, 13:15 ET

DUBLIN, July 10, 2020 /PRNewswire/ -- The "Global Antibody Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Antibodies
Antibody-drug conjugates
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb
Polyclonal Antibodies

Global Antibody Partnering Terms and Agreements 2014 to 2020 includes:

Trends in Antibody dealmaking in the biopharma industry since 2014
Analysis of Antibody deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Antibody deals
Access to over 1,300 Antibody online deal records
The leading Antibody deals by value since 2014
Most active Antibody dealmakers since 2014
The leading Antibody partnering resources

The initial chapters of this report provide an orientation of Antibody dealmaking and business activities.

Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2014, where a contract document is available in the public domain. The Chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2014. The Chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Analyzing actual contract agreements allows assessment of the following:

What are the precise Antibody rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

3SBio
4D Pharma
A*STAR Agency for Science
Technology and Research
A*STAR Singapore Immunology Network
Aarhus University Hospital
Abbvie
Abcam
AbCellera
AbCheck
AbClon
Abcuro
Ab E Discovery
Abeome
Abilita Bio
Ab Initio
ABL Bio
Ablexis
Ablynx
AbMed
Abpro
Abveris
Abzena
Acceleron Pharma
Accord Healthcare
Aceno Biotherapeutics
Acerta Pharma
Achaogen
AC Immune
Acticor Biotech
Actinium Pharmaceuticals
Adagene
AdAlta
Adaptimmune
Adaptive Biotechnologies
ADC Therapeutics
Adimab
Adlai Nortye
Aduro BioTech
Advanced Biological Laboratories
Advanced BioScience Laboratories
Advanced Proteome Therapeutics
Advantagene
Advaxis
Aeglea BioTherapeutics
Aevi Genomic Medicine
AffaMed Therapeutics
Affibody
Affilogic
Affimed Therapeutics
Affinita Biotech
AGC Biologics
Agensys
Agenus Bio
Agilvax
AgomAb Therapeutics
AgonOx
AIMM Therapeutics
Aimmune Therapeutics
Akeso Biopharma
Albert Einstein College of Medicine
Alder Biopharmaceuticals
Alector
Alexion Pharmaceuticals
Allakos
Allele Biotechnology and Pharmaceuticals
Allergan
Alligator Bioscience
Allogene Therapeutics
Almirall
Alpha Cancer Technologies
Alphamab
Alteogen
Alvogen
Alvotech
Alytas Therapeutics
Amag Pharmaceuticals
Ambrx
American Foundation for AIDS Research (amfAR)
Amgen
Amneal Pharmaceuticals
Amplyx Pharmaceuticals
AnaptysBio
AnGes MG
Angiex
Anthera Pharmaceuticals
Anthos Therapeutics
Antidote Therapeutics
Antigen Express
Antikor Biopharma
Antitope
Apceth
Apeiron Biologics
Aperion Biologics
Apexigen
Aptevo Therapeutics
Aquila BioMedical
Arcus Biosciences
arGEN-X
argenx
Aridis Pharmaceuticals
ARMO Biosciences
Array Biopharma
Arsanis Biosciences
Arsia Therapeutics
Ascenion
Ascentage Pharma
Ascletis
Aslan Pharma
Aspyrian Therapeutics
Astellas Pharma
Astex Pharmaceuticals
AstraZeneca
Atara Biotherapeutics
aTen Therapeutics
Athenex
Atlab Pharma
Atlangram
Atlante Biotech
Atreca
Austrian Institute of Technology
Avacta
AvantGen
AVEO Oncology
Avid Bioservices
Avidity Biosciences
Avillion
AxioMx
Aytu BioScience
Back-A-Line
Basilea Pharmaceutica
Batavia Biosciences
Bausch & Lomb
Bavarian Nordic
Baxalta
Baxter International
Bayer
Bayer Healthcare
Baylor Institute for Immunology Research
BB100
BeiGene
Benchwise
BerGenBio
Berkeley Lights
Beth Israel Deaconess Medical Center
Biametrics
Bill and Melinda Gates Foundation
Bio-Techne
Bio-Thera Solutions
BioArctic Neuroscience
biOasis Technologies
BioAtla
Biocare Medical
Bioceros
BiocerOX Products
bioCSL
Biocytogen
Biodesix
BioDuro
Biofactura
Bio Farma
Biogen
BioGenes
BioInvent
BioLegend
BiolineRX
bioLytical Laboratories
BioMarker Strategies
Biomax Informatics
Biomedical Advanced Research and Development Authority
Biomedical Catalyst Fund (UK)
Biomunex Pharmaceuticals
BioNovion
BioNTech
Biooutsource
BioRap Technologies
Biosceptre International
Biotem
Biothera
Biotheus
BioTie Therapies
BioVectra
BioVendor
Bioventix
BioWa
BioXcel
BliNK Biomedical
BliNK Therapeutics
Bliss Biopharmaceutical
Bluebird Bio
Blue Sky Biotech
Boehringer Ingelheim
Bpifrance
Brigham and Women's Hospital
Brii Biosciences
Bristol-Myers Squibb
Broad Institute
C-Bridge Capital
C2N Diagnostics
Caerus Discovery
Caliber Biotherapeutics
and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/hl55c5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets